A comparison of once and twice daily atenolol for angina pectoris

Boyle, R.M.; Bray, Colin; Naqvi, N; Croxson, R. S.; Cruickshank, J. M.

doi:10.1016/0167-5273(83)90058-x

Cited by 7 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Treatment with 0-adrenoceptor blocking agents has become the mainstay of treatment of patients with stable angina of effort and the standard by which the efficacy of other drugs is judged. We have shown that atenolol given in a once daily dosage of 100 mg gives good control of angina and is therefore a suitable agent for such comparisons (Boyle et al, 1983). The present study confirms that oxyfedrine gives significant benefit in patients with angina when given in a dosage of 24 mg four times daily when compared with placebo.…”

Section: Discussionsupporting

confidence: 81%

Comparison of oxyfedrine and atenolol in angina pectoris‐a double‐ blind study.

Fananapazir¹,

Bray²

1985

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 We have compared oxyfedrine 24 mg four times daily with atenolol 100 mg once daily in the relief of angina pectoris in a double-blind cross-over study; assessments were by diary cards and treadmill testing. 2 Both oxyfedrine and atenolol reduced the frequency of angina by similar amounts and both produced similar improvements in treadmill performance. 3 Side effects were infrequent and minor with both drugs. 4 The mode of action of oxyfedrine appears to be different from atenolol. Oxyfedrine allows the double product of systolic blood pressure x heart rate at peak exercise to be maintained at levels similar to those with placebo; the double product at peak exercise is significantly less with atenolol.

show abstract

Section: Discussionsupporting

confidence: 81%

Comparison of oxyfedrine and atenolol in angina pectoris‐a double‐ blind study.

Fananapazir¹,

Bray²

1985

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…In the current study, patients were symptomatic despite receiving maximally tolerated bisoprolol-based therapy, which in the majority of patients was represented by the 5 mg dose. Beta-blockers are often limited by side effects at higher doses, which can decrease patient adherence [39][40][41]. Data from the CLARIFY study have confirmed that in clinical practice, beta-blocker dosing is typically only 50% of the dose range required for demonstration of efficacy in randomized controlled trials [24].…”

Section: Discussionmentioning

confidence: 99%

Effectiveness and Tolerability of Trimetazidine 80 Mg Once Daily in Patients with Stable Angina Uncontrolled with Bisoprolol-Based Therapy: The Modus Vivendi Observational Study

Lopatin

Petrova

2021

Cardiol Ther

View full text Add to dashboard Cite

Introduction: Modus Vivendi was conducted in routine clinical practice to evaluate the effect of adding trimetazidine 80 mg once daily (TMZ 80 OD) to treat patients with persistent symptoms despite treatment with background antianginal therapies including maximally tolerated bisoprolol. Methods: This multicenter, prospective, observational, open-label, uncontrolled study recruited adult outpatients with a confirmed diagnosis of stable angina to whom physicians had decided to prescribe TMZ 80 OD. All patients were symptomatic despite treatment, including maximally tolerated doses of bisoprolol. Data on number of angina attacks, use of short-acting nitrates, and quality of life (QoL) were collected at baseline (V1) and at 1-month (V2) and 3-month (V2) follow-up visits. Two sub-analyses assessed efficacy in patients who remained on a stable bisoprolol dose throughout the study, and in patients in whom background antianginal therapy was known.

show abstract

“…These findings reflect those of the CLARIFY registry study, which demonstrated that the maximum BB dose is often not reached in clinical practice. This registry study found that CCS patients were prescribed a BB dose that was one-half of that used in clinical studies [ 30 ], often because higher BB dosages increase side effects without a relevant efficacy, thereby reducing patient adherence [ 31 , 32 ].…”

Section: Discussionmentioning

confidence: 99%

Trimetazidine and Bisoprolol to Treat Angina in Symptomatic Patients: Post Hoc Analysis From the CHOICE-2 Study

Глезер

2020

Cardiol Ther

View full text Add to dashboard Cite

Introduction: Angina is the cardinal symptom of chronic coronary syndrome (CCS), which is the leading cause of death worldwide. As such, the control of angina is important. The current guidelines recommend beta blockers (BB) or calcium channel blockers to reduce angina, yet many patients with stable angina remain symptomatic. It has been suggested that combining trimetazidine (TMZ), an anti-ischemic agent, with a BB is beneficial for symptomatic patients. Bisoprolol, a BB, is often used to treat patients with CCS, yet no data are currently available regarding the efficacy of bisoprolol combined with TMZ in patients who remain symptomatic despite receiving bisoprolol. Methods: The aim of this post-hoc analysis of the CHOICE-2 study was to evaluate the efficacy and safety of TMZ 35 mg twice daily in combination with different bisoprolol doses in symptomatic patients with stable angina patients receiving hemodynamic therapy in a real-world clinical setting. Results: This analysis involved 221 patients (mean [± standard deviation] age 64.8 ± 8.9 years) with stable angina. The mean number of weekly angina episodes gradually fell from 6.2 ± 5.3 at inclusion (M0) to 1.5 ± 1.9 at 6 months after treatment initiation (M6) with combined TMZ-bisoprolol therapy (P \ 0.001). The number of patients assessed to be anginafree increased almost sixfold from 5.4% (12/ 221) at M0 to 33.9% (74/221) at M6. Exercise capacity improved, as measured by walking distance, from 308 ± 207 m at M0 to 497 ± 253 m at M6 (P \ 0.05). The number of patients with Canadian Cardiovascular Society class 1 angina increased by tenfold during the study, whereas those with class 3 angina decreased by threefold. Conclusion: The TMZ-bisoprolol combination is a rapidly effective treatment for reducing the frequency of angina attacks and the use of short-acting nitrates in patients with stable angina in a real-world clinical setting. The benefits of this combination therapy was observed as early as 2 weeks after treatment initiation and the treatment was well tolerated. Trial Registration: ISRCTN identifier: ISRCTN65209863

show abstract

A comparison of once and twice daily atenolol for angina pectoris

Cited by 7 publications

References 11 publications

Comparison of oxyfedrine and atenolol in angina pectoris‐a double‐ blind study.

Comparison of oxyfedrine and atenolol in angina pectoris‐a double‐ blind study.

Effectiveness and Tolerability of Trimetazidine 80 Mg Once Daily in Patients with Stable Angina Uncontrolled with Bisoprolol-Based Therapy: The Modus Vivendi Observational Study

Trimetazidine and Bisoprolol to Treat Angina in Symptomatic Patients: Post Hoc Analysis From the CHOICE-2 Study

Contact Info

Product

Resources

About